Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2008 Jan 28;7(4):1131–1136. doi: 10.1111/j.1750-3639.1997.tb00993.x

Genetics of Glioma Progression and the Definition of Primary and Secondary Glioblastoma

Paul Kleihues 1, Hiroko Ohgaki 1
PMCID: PMC8098145

Summary

Glioblastoma multiforme, the most malignant human brain tumor, may develop de novo (primary glioblastoma) or through progression from low‐grade or anaplastic astrocytoma (secondary glioblastoma). We present evidence that these subtypes of glioblastoma constitute distinct disease entities which evolve through different genetic pathways, affect patients at different age and are likely to differ in prognosis and response to therapy. Primary glioblastomas develop in older patients (mean, 55 years) and typically show EGFR overexpres‐sion or, less frequently, MDM2 overexpression and pi6 deletion. Secondary glioblastomas develop in younger patients (mean, 40 years) and frequently contain TP53 mutations and, less consistently, loss of DCC expression. Although primary and secondary glioblastomas are considered to be histologically indistinguishable, we found that the pattern and pathogenesis of necrosis are different, large areas of ischaemic necrosis surrounded by Fas expressing tumor cells being a hallmark of primary glioblastomas. The giant cell glioblastoma occupies an intermediate position. Like the primary glioblastoma, it rapidly develops de novo but manifests in younger patients (including children) and has genetic alterations typical for secondary glioblastomas, i.e. frequent TP53 mutations and lack of EGFR overexpression.

Full Text

The Full Text of this article is available as a PDF (437.8 KB).

References

  • 1. Barak Y, Gottlieb E, Juven Gershon T, Oren M. (1994) Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 8: 1739–1749. [DOI] [PubMed] [Google Scholar]
  • 2. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H. (1996) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180–185. [DOI] [PubMed] [Google Scholar]
  • 3. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. (1997) Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas, in preparation. [DOI] [PubMed]
  • 4. Burger PC, Kleihues P. (1989) Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies. Cancer 63: 2014–2023. [DOI] [PubMed] [Google Scholar]
  • 5. Burger PC, Scheithauer BW. (1994) Tumors of the Central Nervous System. Armed Forces Institute of Pathology: Washington . [Google Scholar]
  • 6. Claesson Welsh L. (1994) Platelet‐derived growth factor receptor signals. J Biol Chem 269: 32023–32026. [PubMed] [Google Scholar]
  • 7. Ekstrand AJ, Sugawa N, James CD, Collins VP. (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N‐ and/or C‐terminal tails. Proc Natl Acad Sci U S A 89: 4309–4313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Fearon ER, Cho KR, Nigra JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW, et al. (1990) Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247: 49–56. [DOI] [PubMed] [Google Scholar]
  • 9. Haffner R, Oren M. (1995) Biochemical properties and biological effects of p53. Curr Opin Genet Dev 5: 84–90. [DOI] [PubMed] [Google Scholar]
  • 10. Hainaut P. (1995) The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol 7: 76–82. [PubMed] [Google Scholar]
  • 11. Heldin CH, Westermark B. (1990) Platelet‐derived growth factor: mechanism of action and possible in vivo function. Cell Regul 1: 555–566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, Heldin CH, Wiestier OD, Louis DN, von Deimling A, Nister M. (1996) Association of loss of heterozygosity on chromosome 17p with high platelet‐derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 56: 164–171. [PubMed] [Google Scholar]
  • 13. Kleihues P, Burger PC, Scheithauer BW. (1993) Histological Typing of Tumours of the Central Nervous System. World Health Organization International Histological Classification of Tumours. 2nd edition, Springer Verlag: Berlin Heidelberg . [Google Scholar]
  • 14. Lantos PL, Vanden Berg SR, Kleihues P. (1996) In: Tumours of the Nervous System, Graham DI, Lantos PL, (eds), Greenfield's Neuropathology. 9, 6th Edition, pp. 583–879, Arnold: London . [Google Scholar]
  • 15. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947. [DOI] [PubMed] [Google Scholar]
  • 16. Ohgaki H, Schauble B, zur Hausen A, von Ammon K, Kleihues P. (1995) Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 427: 113–118. [DOI] [PubMed] [Google Scholar]
  • 17. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ. (1993) Identification and characterization of multiple mdm‐2 proteins and mdm‐2‐p53 protein complexes. Oncogene 8: 2353–2360. [PubMed] [Google Scholar]
  • 18. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ueki K, Louis DN. (1996) Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have h gher Ki‐67 proliferation indices. J Neuropathol Exp Neurol 55: 1026–103. [PubMed] [Google Scholar]
  • 19. Peraud A, Watanabe K, Plate KH, Yonekawa Y, Kleihues P, Ohgaki H. (1997) p53 Mutations vs. EGFR expression in giant cell glioblastomas. J Neuropath Exp Neurol in preparation:. [DOI] [PubMed] [Google Scholar]
  • 20. Picksley SM, Lene DP. (1993) The p53‐mdm2 autoregu‐latory feedback loop: a paradigm for the regulation of growth control by p53 Bioessays 15: 689–690. [DOI] [PubMed] [Google Scholar]
  • 21. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. (1993) Amplification and overexpression of the MDM2 gene in a subse of human malignant gliomas without p53 mutations. Cancer Res 53: 2736–2739. [PubMed] [Google Scholar]
  • 22. Reyes‐Mugica M, Rieger‐Christ K, Ohgaki H, Ekstrand BC, Helie M, Kleinman G, Yahanda A, Fearon ER, Kleihues P, Reale MA. (1997) Loss of DCC expression and glioma progression. Cancer Res 57: 382–386. [PubMed] [Google Scholar]
  • 23. Russell DS, Rubinstein LJ. (1989) Pathology of Tumours of the Nervous System. 5th edition, Edward Arnold: London . [Google Scholar]
  • 24. Scherer HJ. (1940) Cerebral astrocytomas and their derivatives. Am J Cancer 40: 159–198. [Google Scholar]
  • 25. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier J, Davies T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 15: 356–362. [DOI] [PubMed] [Google Scholar]
  • 26. Tohma Y, Gratas C, Van Meir E, xxxx, Desbaillets I , Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H. (1997) Fas/APO‐1(CD95) expression in primary and secondary glioblastoma. J Neuropath Exp Neurol. [DOI] [PubMed] [Google Scholar]
  • 27. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL, Schoenfeld DA, Yasargil MG, Wiestier OD, Seizinger BR. (1992) Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 77: 295–301. [DOI] [PubMed] [Google Scholar]
  • 28. von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestier OD, Seizinger BR. (1992) Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocy:omas, oligodendrogliomas, and mixed gliomas. Cancer Res 52: 4277–4279. [PubMed] [Google Scholar]
  • 29. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Oga:a N, Yonekawa Y, Kleihues P, Ohgaki H. (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3: 523–530. [PubMed] [Google Scholar]
  • 30. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H. (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217–224. [DOI] [PubMed] [Google Scholar]
  • 31. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B. (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89: 2965–2969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. (1995) A functional p53‐responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 23: 2584–2592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Zulch KJ. (1986) Brain Tumors. Their biology and pathology. 3rd edition, Springer Verlag: Berlin Heidelberg . [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES